blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2342177

EP2342177 - NOVEL POTASSIUM CHANNEL BLOCKERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.12.2017
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  13.01.2017
FormerGrant of patent is intended
Status updated on  06.01.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Japan Tobacco Inc.
2-1 Toranomon 2-chome, Minato-ku
Tokyo 105-8422 / JP
[2016/02]
Former [2011/28]For all designated states
Xention Limited
Iconix Park London Road Pampisford
Cambridgeshire CB22 3EG / GB
Inventor(s)01 / JOHN, Derek, Edward
Xention Limited
Iconix Park
London Road
Pampisford
Cambridgeshire CB22 3EG / GB
02 / MULLA, Mushtaq
Xention Limited
Iconix Park
London Road
Pampisford
Cambridgeshire CB22 3EG / GB
03 / HAMLYN, Richard, John
Xention Limited
Iconix Park
London Road
Pampisford
Cambridgeshire CB22 3EG / GB
04 / GARRETT, Sasha, Louise
Xention Limited
Iconix Park
London Road
Pampisford
Cambridgeshire CB22 3EG / GB
05 / HARTZOULAKIS, Basil
Xention Limited
Iconix Park
London Road
Pampisford
Cambridgeshire CB22 3EG / GB
06 / MADGE, David
Xention Limited
Iconix Park
London Road
Pampisford
Cambridgeshire CB22 3EG / GB
07 / FORD, John
Xention Limited
Iconix Park
London Road
Pampisford
Cambridgeshire CB22 3EG / GB
 [2015/33]
Former [2011/28]01 / JOHN, Derek, Edward
Xention Limited Iconix Park London Road Pampisford
Cambridgeshire CB22 3EG / GB
02 / MULLA, Mushtaq
Xention Limited Iconix Park London Road Pampisford
Cambridgeshire CB22 3EG / GB
03 / HAMLYN, Richard, John
Xention Limited Iconix Park London Road Pampisford
Cambridgeshire CB22 3EG / GB
04 / GARRETT, Sarah, Louise
Xention Limited Iconix Park London Road Pampisford
Cambridgeshire CB22 3EG / GB
05 / HARTZOULAKIS, Basil
Xention Limited Iconix Park London Road Pampisford
Cambridgeshire CB22 3EG / GB
06 / MADGE, David
Xention Limited Iconix Park London Road Pampisford
Cambridgeshire CB22 3EG / GB
07 / FORD, John
Xention Limited Iconix Park London Road Pampisford
Cambridgeshire CB22 3EG / GB
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
P.O. Box 86 07 67
81634 München / DE
[2017/07]
Former [2011/28]Chapman, Paul William, et al
Kilburn & Strode LLP 20 Red Lion Street London
WC1R 4PJ / GB
Application number, filing date09785012.727.08.2009
[2011/28]
WO2009GB02078
Priority number, dateGB2008001578229.08.2008         Original published format: GB 0815782
US20080093233P29.08.2008         Original published format: US 93233 P
[2011/28]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010023448
Date:04.03.2010
Language:EN
[2010/09]
Type: A1 Application with search report 
No.:EP2342177
Date:13.07.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 04.03.2010 takes the place of the publication of the European patent application.
[2011/28]
Type: B1 Patent specification 
No.:EP2342177
Date:15.02.2017
Language:EN
[2017/07]
Search report(s)International search report - published on:EP04.03.2010
ClassificationIPC:C07C311/21, C07D207/12, C07D209/08, C07D211/08, C07D213/04, C07D231/00, C07D233/54, C07D265/30, C07D265/36, C07D271/08, C07D277/32, C07D285/135, C07D307/79, C07D311/70, C07D317/62, C07D319/18, C07D401/12, C07D413/12, A61K31/18, A61P29/00
[2015/31]
CPC:
C07C311/21 (EP,US); A61P17/06 (EP); A61P19/02 (EP);
A61P25/00 (EP); A61P29/00 (EP); A61P37/00 (EP);
C07C311/46 (EP,US); C07C317/32 (US); C07C317/40 (US);
C07D207/12 (EP,US); C07D209/08 (EP,US); C07D211/16 (EP,US);
C07D211/34 (EP,US); C07D211/44 (EP,US); C07D213/36 (EP,US);
C07D213/40 (EP,US); C07D213/71 (EP,US); C07D231/12 (EP,US);
C07D231/18 (EP,US); C07D231/56 (EP,US); C07D233/61 (EP,US);
C07D233/64 (EP,US); C07D233/84 (EP,US); C07D265/30 (EP,US);
C07D265/36 (EP,US); C07D271/08 (EP,US); C07D277/28 (EP,US);
C07D277/36 (EP,US); C07D277/46 (EP,US); C07D285/12 (EP,US);
C07D285/135 (EP,US); C07D307/79 (EP,US); C07D311/70 (EP,US);
C07D317/62 (EP,US); C07D319/18 (EP,US); C07D401/12 (EP,US);
C07D403/12 (EP,US); C07D413/12 (EP,US); C07C2601/02 (EP,US);
C07C2601/04 (EP,US); C07C2601/08 (EP,US) (-)
Former IPC [2011/28]C07C311/21, C07D205/04, C07D211/08, C07D213/04, C07D231/00, C07D233/54, C07D265/28, C07D271/12, C07D277/32, C07D307/79, C07D311/70, C07D317/62, C07D319/18, A61K31/18, A61P29/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2017/07]
Former [2011/28]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:NEUE KALIUMKANALBLOCKER[2011/28]
English:NOVEL POTASSIUM CHANNEL BLOCKERS[2011/28]
French:NOUVEAUX BLOQUANTS DU CANAL POTASSIQUE[2011/28]
Entry into regional phase14.03.2011National basic fee paid 
14.03.2011Designation fee(s) paid 
14.03.2011Examination fee paid 
Examination procedure14.03.2011Amendment by applicant (claims and/or description)
14.03.2011Examination requested  [2011/28]
08.11.2012Despatch of a communication from the examining division (Time limit: M04)
18.03.2013Reply to a communication from the examining division
16.04.2014Despatch of a communication from the examining division (Time limit: M06)
24.10.2014Reply to a communication from the examining division
17.07.2015Communication of intention to grant the patent
12.01.2016Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
22.03.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
02.05.2016Communication of intention to grant the patent
12.09.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
12.09.2016Fee for grant paid
12.09.2016Fee for publishing/printing paid
17.10.2016Communication of intention to grant the patent
22.12.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.11.2012
Opposition(s)16.11.2017No opposition filed within time limit [2018/04]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
22.03.2016Request for further processing filed
22.03.2016Full payment received (date of receipt of payment)
Request granted
06.04.2016Decision despatched
Fees paidRenewal fee
11.08.2011Renewal fee patent year 03
10.08.2012Renewal fee patent year 04
19.08.2013Renewal fee patent year 05
13.08.2014Renewal fee patent year 06
25.08.2015Renewal fee patent year 07
26.08.2016Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.08.2009
AT15.02.2017
CY15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
MC15.02.2017
MK15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
SM15.02.2017
TR15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
IS15.06.2017
PT15.06.2017
IE27.08.2017
LU27.08.2017
MT27.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
[2020/33]
Former [2020/15]HU27.08.2009
AT15.02.2017
CY15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
MC15.02.2017
MK15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
SM15.02.2017
TR15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
IE27.08.2017
LU27.08.2017
MT27.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
Former [2019/51]HU27.08.2009
AT15.02.2017
CY15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
MC15.02.2017
MK15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
SM15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
IE27.08.2017
LU27.08.2017
MT27.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
Former [2019/46]HU27.08.2009
AT15.02.2017
CY15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
SM15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
IE27.08.2017
LU27.08.2017
MT27.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
Former [2019/31]HU27.08.2009
AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
SM15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
IE27.08.2017
LU27.08.2017
MT27.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
Former [2018/43]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
SM15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
IE27.08.2017
LU27.08.2017
MT27.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
Former [2018/39]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
SM15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
IE27.08.2017
LU27.08.2017
BE31.08.2017
CH31.08.2017
LI31.08.2017
Former [2018/34]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
SM15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
IE27.08.2017
LU27.08.2017
CH31.08.2017
LI31.08.2017
Former [2018/21]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
SM15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
CH31.08.2017
LI31.08.2017
Former [2018/18]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
SM15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
Former [2018/14]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
SM15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
Former [2017/51]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SK15.02.2017
SM15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
Former [2017/50]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SK15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
Former [2017/49]AT15.02.2017
CZ15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
IT15.02.2017
LT15.02.2017
LV15.02.2017
NL15.02.2017
RO15.02.2017
SE15.02.2017
SK15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
Former [2017/48]AT15.02.2017
CZ15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
LT15.02.2017
LV15.02.2017
NL15.02.2017
SE15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
Former [2017/41]AT15.02.2017
ES15.02.2017
FI15.02.2017
HR15.02.2017
LT15.02.2017
LV15.02.2017
NL15.02.2017
SE15.02.2017
BG15.05.2017
NO15.05.2017
GR16.05.2017
PT15.06.2017
Cited inInternational search[A]US2006183768  (FORD JOHN [GB], et al) [A] 1-22 * claims 1, 7, 12, 14 *;
 [A]US2002006929  (GROSS MICHAEL [US], et al) [A] 1-22 * claims 1, 5, 7, 11, 13-15 *;
 [X]US2004077696  (BORZILLERI ROBERT M [US], et al) [X] 1-2,7-9,13-22 * paragraphs [0086] , [0103]; example 9 *;
 [X]US5721255  (HOWARD HARRY R [US], et al) [X] 1,6,8-9,13-18,20-21 * column 12, lines 42-63; example 57; claim 12 *;
 [X]WO2007110171  (BAYER HEALTHCARE AG [DE], et al) [X] 1-2,4-10,13-14 * examples 20,21; claims 1,5 *;
 [X]US2006258728  (TANI KOUSUKE [JP], et al) [X] 1-2,6,8-9,13-14 * example 6(270); claims 1, 10, 16; compound 791 *;
 [X]US2006116410  (BANNER DAVID W [CH], et al) [X] 1-2,6,8-9,13-14 * examples 140, 141, 151-157, 159, 162, 163, 171, 172; claims 1, 45 *;
 [X]WO2005030709  (LG LIFE SCIENCES LTD [KR], et al) [X] 1-2,6-9,13-14 * claims 1, 6, 12; compound 9; * * preparation examples 43, 44 *
 [AD]  - HANSON DOUGLAS C ET AL, "UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation", BRITISH JOURNAL OF PHARMACOLOGY, NATURE PUBLISHING GROUP, BASINGSTOKE, HANTS, (19990101), vol. 126, ISSN 0007-1188, pages 1707 - 1716, XP008091174 [AD] 1-22 * page 1709, column r - page 1710, column r; figure 1; table 1 *

DOI:   http://dx.doi.org/10.1038/sj.bjp.0702480
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.